Faes Farma 9M 2026 Operating Profit Rises 7% to EUR 94.48 Million
- Faes Farma’s consolidated profit for the first nine months of 2026 rose to €74.28 million.
- Revenue climbed 24% to €563.54 million, driven by acquisitions and strong international growth.
- Bilastine licence revenue fell 23% to €59 million due to generic competition in Japan.
- The integration of SIFI and Edol remained on schedule, with ophthalmology revenue reaching €96.8 million.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Faes Farma SA published the original content used to generate this news brief on October 29, 2026, and is solely responsible for the information contained therein.